GlassScriptPhysician profile
Matthew P Jones
NPI 1548255755
$582.68
in general payments reported to CMS, 2019-2025
18 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.94 · 2020: $16.50 · 2021: $15.53 · 2022: $52.00 · 2023: $105 · 2024: $139 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $125.00 | 2025 | Kimmtrak |
| Pfizer INC. | $58.55 | 2019-2025 | |
| Mirati Therapeutics, INC. | $44.49 | 2023-2024 | Krazati |
| Janssen Biotech, INC. | $41.27 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $34.64 | 2023 | Imbruvica |
| Array Biopharma INC | $34.62 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Abbvie INC. | $31.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.18 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.71 | 2025 | Libtayo |
| Iovance Biotherapeutics, INC. | $20.36 | 2024 | Amtagvi |
| Beigene USA, INC. | $19.72 | 2022 | |
| Merck Sharp & Dohme LLC | $19.61 | 2025 | Keytruda |
| Amneal Pharmaceuticals LLC | $19.04 | 2025 | Alymsys |
| Incyte Corporation | $17.61 | 2023 | Jakafi |
| Cti Biopharma Corp. | $17.32 | 2023 | Vonjo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.50 | 2020 | |
| Philips North America LLC | $15.54 | 2024 | (Ck7) Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.